Reproductive · FDA Approved
Goserelin (Zoladex)
FDA-approved
01 · Overview
A synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug release over 1 or 3 months. Like other GnRH agonists, goserelin initially stimulates and then suppresses the HPG axis, reducing sex hormone production to castrate or postmenopausal levels.
The implant formulation reduces the frequency of injections compared with daily dosing.
02 · Research summary & key findings
FDA-approved (Zoladex) for prostate cancer, advanced breast cancer in pre- and perimenopausal women, endometriosis, and endometrial thinning before ablation. The 3-month depot suppressed testosterone to the castration range by week 4 and maintained suppression throughout a multicenter trial (PMID 12740498). In a randomized trial in metastatic prostate cancer, goserelin was as effective as orchiectomy for response, time to treatment failure, and survival (PMID 7624991). In the EORTC trial of locally advanced prostate cancer, adding goserelin to radiotherapy improved 5-year overall survival from 62% to 79% (Bolla et al., NEJM, 1997) (PMID 9233866).
03 · Regulatory status
Goserelin (Zoladex) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Goserelin (Zoladex) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Goserelin (Zoladex) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous implant
References
- [1]3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial Urol Int, 2003. PMID 12740498
- [2]Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group Urology, 1995. PMID 7624991
- [3]Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med, 1997. PMID 9233866
Primary literature
- PubMed: "Goserelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Goserelin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Goserelin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Reproductive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.